News Articles and Montana BioScience Alliance Newsletters
University of Montana first-year student Tori Matteson can’t point to a specific event that peaked her interest in becoming a pharmacist – there aren’t any in her family – but her curiosity about medicine started early in her high school years growing up in Butte. When it came time to enroll in college…she said it was “UM all the way.”
Montana company Solo-Dex has entered into an agreement for its proprietary continuous nerve block catheters with InfuSystem, a leading national healthcare service provider.
As research programs grow at the University of Montana, a team of vaccine scientists are making headway into long-term COVID-19 prevention and clinical trials for an opioid vaccine.
Billings Clinic is participating in a national trial to study the use of an advanced device to treat patients with atrial fibrillation who are at higher risk for stroke and we are enrolling participants now. Called the CHAMPION-AF trial and initiated by Boston Scientific, it is a randomized head-to-head trial designed to evaluate the safety and efficacy of the next-generation WATCHMAN FLX Left Atrial Appendage Closure Device within a broad population of patients with non-valvular atrial fibrillation (AF), including those who are […]
Bio event draws about 3,000 companies to the San Diego Convention Center to take stock of the latest trends and research.
Four-time gold medalist and seven-time Grand Slam singles champion Venus Williams will discuss her groundbreaking career, business success, and prioritizing health in a conversation moderated by Emmy-nominated sports reporter Erin Andrews at the BIO International Convention June 13-16, 2022, in San Diego. Both women have faced their own health challenges, becoming advocates for increased awareness and better outcomes for all.
As the pandemic enters its third year, long Covid has emerged as an increasingly important concern. And many people are wondering whether getting a Covid shot can reduce their chances of developing long-term symptoms.
Congress has returned to Capitol Hill, and among the most important unfinished business on its agenda is agreeing to a new package to fight COVID-19 by funding second-generation vaccine research. When Congress left town, there was cautious optimism that a deal was close.
Thirty regional companies will be selected to present at the Rocky Mountain Life Sciences Investor & Partnering Conference. Companies seeking seed, early-stage, late-stage funding in the medical device, diagnostic, biotech, pharmaceutical, and digital health sectors are encouraged to apply.